JP5026635B2 - 医薬物質の迅速放出医薬組成物 - Google Patents

医薬物質の迅速放出医薬組成物 Download PDF

Info

Publication number
JP5026635B2
JP5026635B2 JP2000569779A JP2000569779A JP5026635B2 JP 5026635 B2 JP5026635 B2 JP 5026635B2 JP 2000569779 A JP2000569779 A JP 2000569779A JP 2000569779 A JP2000569779 A JP 2000569779A JP 5026635 B2 JP5026635 B2 JP 5026635B2
Authority
JP
Japan
Prior art keywords
composition
dissolution
substance
particle size
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000569779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002524492A (ja
JP2002524492A5 (https=
Inventor
ポウル・ベルテルセン
ニルス・グイェルロヴ・ハンセン
ヘルマン・ルッケノルファー
茂 板井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Publication of JP2002524492A publication Critical patent/JP2002524492A/ja
Publication of JP2002524492A5 publication Critical patent/JP2002524492A5/ja
Application granted granted Critical
Publication of JP5026635B2 publication Critical patent/JP5026635B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000569779A 1998-09-10 1999-09-10 医薬物質の迅速放出医薬組成物 Expired - Lifetime JP5026635B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801143 1998-09-10
DK199801143 1998-09-10
DKPA199801143 1998-09-10
PCT/DK1999/000480 WO2000015195A1 (en) 1998-09-10 1999-09-10 Quick release pharmaceutical compositions of drug substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011227314A Division JP5622703B2 (ja) 1998-09-10 2011-10-14 医薬物質の迅速放出医薬組成物

Publications (3)

Publication Number Publication Date
JP2002524492A JP2002524492A (ja) 2002-08-06
JP2002524492A5 JP2002524492A5 (https=) 2006-11-24
JP5026635B2 true JP5026635B2 (ja) 2012-09-12

Family

ID=8101500

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000569779A Expired - Lifetime JP5026635B2 (ja) 1998-09-10 1999-09-10 医薬物質の迅速放出医薬組成物
JP2011227314A Expired - Lifetime JP5622703B2 (ja) 1998-09-10 2011-10-14 医薬物質の迅速放出医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011227314A Expired - Lifetime JP5622703B2 (ja) 1998-09-10 2011-10-14 医薬物質の迅速放出医薬組成物

Country Status (13)

Country Link
US (1) US6713089B1 (https=)
EP (1) EP1109534B1 (https=)
JP (2) JP5026635B2 (https=)
AT (1) ATE232382T1 (https=)
AU (1) AU5504599A (https=)
CA (1) CA2343148C (https=)
DE (1) DE69905380T2 (https=)
DK (1) DK1109534T3 (https=)
EA (1) EA004032B1 (https=)
ES (1) ES2190241T3 (https=)
PT (1) PT1109534E (https=)
TR (1) TR200100708T2 (https=)
WO (1) WO2000015195A1 (https=)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030161875A1 (en) * 2002-02-27 2003-08-28 Deepak Murpani Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GEP20094671B (en) * 2004-06-29 2009-04-27 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
JP5490347B2 (ja) * 2005-05-27 2014-05-14 エスエス製薬株式会社 経口投与用製剤
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
CA2614850A1 (en) 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2661818A1 (en) * 2006-05-03 2007-11-15 Kowa Pharmaceuticals America, Inc. Acute pain medications based on fast acting diclofenac-opioid combinations
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
WO2008062449A2 (en) * 2006-09-18 2008-05-29 Glenmark Pharmaceuticals Limited A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
EP3070090B1 (en) * 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
PL2224914T3 (pl) 2007-09-14 2015-11-30 Wockhardt Ltd Kompozycje diacereiny
PL2240018T3 (pl) * 2008-01-04 2017-01-31 Schabar Res Ass Llc Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
RU2010151953A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Карбонатные продукты и способы их применения
KR101698028B1 (ko) 2008-05-20 2017-01-26 노이로제스엑스, 인코포레이티드 수용성 아세트아미노펜 유사체
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
MX389960B (es) 2009-10-12 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Recipientes para composiciones que comprenden meloxicam.
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012146314A1 (en) 2011-04-29 2012-11-01 Refarmed Chemicals Sa Thin gelatin capsules for rapid drug release in the mouth
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP2012012411A (ja) * 2011-10-03 2012-01-19 Ssp Co Ltd 経口投与用製剤
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
JP2013216701A (ja) * 2013-07-29 2013-10-24 Ssp Co Ltd 経口投与用製剤
KR101890649B1 (ko) * 2013-07-30 2018-09-28 라이온 가부시키가이샤 정제
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
PT3164117T (pt) 2014-07-03 2023-12-12 SpecGx LLC Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos
US10662146B2 (en) 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
UA126916C2 (uk) 2017-04-27 2023-02-22 Др. Редді'З Лабораторіз Лімітед Фармацевтична композиція кеторолаку
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
JP7170437B2 (ja) * 2018-06-29 2022-11-14 小林製薬株式会社 内服用医薬組成物
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
JP7499025B2 (ja) * 2019-12-27 2024-06-13 小林製薬株式会社 内服用医薬組成物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
EP4181912A1 (en) 2020-07-15 2023-05-24 Schabar Research Associates LLC Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965072A (en) * 1988-11-03 1990-10-23 Miles Inc. Granulating composition and method
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
JP2906528B2 (ja) * 1990-02-14 1999-06-21 大正製薬株式会社 吸収を促進した内服用固形製剤
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
EP1109534A1 (en) 2001-06-27
ATE232382T1 (de) 2003-02-15
WO2000015195A1 (en) 2000-03-23
JP2002524492A (ja) 2002-08-06
JP2012082197A (ja) 2012-04-26
JP5622703B2 (ja) 2014-11-12
DK1109534T3 (da) 2003-06-10
AU5504599A (en) 2000-04-03
EA200100331A1 (ru) 2001-08-27
EP1109534B1 (en) 2003-02-12
DE69905380D1 (de) 2003-03-20
US6713089B1 (en) 2004-03-30
CA2343148C (en) 2005-11-15
CA2343148A1 (en) 2000-03-23
EA004032B1 (ru) 2003-12-25
PT1109534E (pt) 2003-06-30
ES2190241T3 (es) 2003-07-16
TR200100708T2 (tr) 2001-07-23
DE69905380T2 (de) 2003-11-27

Similar Documents

Publication Publication Date Title
JP5026635B2 (ja) 医薬物質の迅速放出医薬組成物
JP7627302B2 (ja) パルボシクリブの固形剤形
US6599529B1 (en) Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
AU2012311293B2 (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
KR100875299B1 (ko) 비수용성 약물의 속방성 약학 조성물 제조 방법 및 상기방법에 의하여 얻어지는 약학 조성물
CN103402497A (zh) 快速分散颗粒、口腔崩解片以及方法
US8231899B2 (en) Quick release pharmaceutical compositions of drug substances
TWI387465B (zh) 具有改良之藥物動力學性質之藥物配製物
WO2006022996A2 (en) Dosage form containing multiple drugs
US8951504B2 (en) (trimethoxyphenylamino) pyrimidinyl formulations
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
WO2009084041A2 (en) Pharmaceutical compositions of dexibuprofen
EP3930691A1 (en) Pharmaceutical composition containing acetominophen and ibuprofen
HK40063384A (en) Solid dosage forms of palbociclib

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100614

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100716

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120605

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120621

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5026635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term